Vitamin K2
Based on 2 publication(s) in Google Scholar
Vitamin K2 is an orally active proliferation inhibitor. Vitamin K2 induces Autophagy and Apoptosis. Vitamin K2 reduces the levels of proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6). Vitamin K2 inhibits cell growth in leukemia cells. Vitamin K2 can be used for the research of involutional osteoporosis, non-alcoholic fatty liver disease, ulcerative colitis, acute myeloid leukemia, myelodysplastic syndromes, and hepatocellular carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 11032-49-8
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Vitamin K2
More
Biological Activity
|
IL-6 |
IL-1β |
Vitamin K2 (10-9-10-5 M; 3 days) dose-dependently suppresses the proliferation of human osteosarcoma HOS TE85 cells (maximal effect at 10-7 M, reducing cell number to 56% of control) and murine osteoblastic MC3T3-E1 cells (maximal effect at 10-6 M, reducing cell number to 84% of control) after 3 days of incubation, and this suppressive effect is reversed by co-incubation with warfarin[1].
Vitamin K2 (6-14 μM; 96 h) inhibits the growth of HL-60neo human leukemia cells with an IC50 of 6 μM and HL-60bcl-2 human leukemia cells with an IC50 of 14 μM after 96-hour exposure[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60neo, HL-60bcl-2 human leukemia cell lines
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:72 h
-
Result:Increased the percentage of cells with bright red fluorescence (AVOs) from 4.8% to 46.8% in HL-60neo cells and from 4.7% to 47.3% in HL-60bcl-2 cells at 10 μM.
Vitamin K2 (15-60 mg/kg; p.o.; 14 days) alleviates dextran sulfate sodium (DSS)-induced ulcerative colitis in male C57BL/6J mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 7 weeks old, DSS-induced ulcerative colitis)[3]
-
Dosage:15 mg/kg·bw; 30 mg/kg·bw; 60 mg/kg·bw
-
Administration:i.g.; daily; 14 days
-
Result:Restored body weight, reduced Disease Activity Index (DAI) score, increased colon length.
Reduced spleen weigh, improved colonic histopathology, restored goblet cell numbers.
Reduced colonic IL-1β and TNF-α levels, increased colonic IL-10 levels, elevated colonic ZO-1, occludin, and muc2 protein expression, reversed DSS-induced increases in Deferribacteres abundance.
Increased fecal acetic acid, propionic acid, and total SCFA levels at 15 mg/kg·bw.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 11032-49-8
-
Appearance Solid
-
Color Light yellow to yellow
-
SMILES
[Vitamin K2]
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Agric Food Chem
A Novel Anti-Osteoporosis Mechanism of VK2: Interfering with Ferroptosis via AMPK/SIRT1 Pathway in Type 2 Diabetic Osteoporosis. [Abstract]2023 Feb 15;71(6):2745-2761. PMID: 36719855 -
Ren Fail
2025 Dec;47(1):2552913. PMID: 40898827
Solvent & Solubility
DMSO : 50 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Akedo Y, et al. Vitamin K2 modulates proliferation and function of osteoblastic cells in vitro. Biochem Biophys Res Commun. 1992;187(2):814-820. [Content Brief]
[2]. Zhao P, et al. Vitamin K2 protects mice against non-alcoholic fatty liver disease induced by high-fat diet. Sci Rep. 2024;14(1):3075. Published 2024 Feb 6. [Content Brief]
[3]. Hu S, et al. Ameliorating Effects of Vitamin K2 on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice. Int J Mol Sci. 2023;24(3):2986. Published 2023 Feb 3. [Content Brief]
[4]. Yokoyama T, et al. Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells. Autophagy. 2008;4(5):629-640. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vitamin K2 Related Classifications
Cat. No.: HY-109569
Powered by Bioz
- Vitamin K2
- 11032-49-8
- Vitamin K 2
- Vitamin K-2
- Autophagy
- Apoptosis
- Interleukin Related
- osteoblastic cells
- colitis mice
- osteosarcoma cells
- C57BL/6J mice
- non-alcoholic fatty liver disease mice
- HL-60neo human leukemia cells
- γ-carboxyglutamic acid
- C57BL/6 male mice
- HL-60bcl-2 human leukemia cells
- γ-carboxylase
- Inhibitor
- inhibitor
- inhibit